Literature DB >> 1359646

Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector.

S Chatterjee1, P R Johnson, K K Wong.   

Abstract

An adeno-associated virus vector encoding an antisense RNA was used to transduce stable intracellular resistance to human immunodeficiency virus-1 (HIV-1) in human hemopoietic and non-hemopoietic cell lines. The antisense targets are present in all HIV-1 transcripts and include the TAR sequence, which is critical for transcription and virus replication, and the polyadenylation signal. Cell lines expressing antisense RNA showed up to 95 percent inhibition of gene expression directed by the HIV-1 long terminal repeat and greater than 99 percent reduction in infectious HIV-1 production, with no detectable cellular toxicity. Because of their efficient transcription and inability to recombine with HIV-1, adeno-associated virus vectors represent a promising form of anti-retroviral gene therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359646     DOI: 10.1126/science.1359646

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  45 in total

Review 1.  Gene therapy for HIV.

Authors:  A M Lever
Journal:  Sex Transm Infect       Date:  2001-04       Impact factor: 3.519

Review 2.  Designing antisense to inhibit the renin-angiotensin system.

Authors:  D Mohuczy; M I Phillips
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

3.  Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response.

Authors:  Ghislaine Gallez-Hawkins; Maria C Villacres; Xiuli Li; Margaret C Sanborn; Norma A Lomeli; John A Zaia
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

4.  Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2.

Authors:  M Ariel Kauss; Laura J Smith; Li Zhong; Arun Srivastava; K K Wong; Saswati Chatterjee
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

Review 5.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

6.  A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines.

Authors:  M Y Chang; S J Won; H S Liu
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

Review 7.  Vectors for cancer gene therapy.

Authors:  J Zhang; S J Russell
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

8.  Recombinant adeno-associated virus mediates a high level of gene transfer but less efficient integration in the K562 human hematopoietic cell line.

Authors:  P Malik; S A McQuiston; X J Yu; K A Pepper; W J Krall; G M Podsakoff; G J Kurtzman; D B Kohn
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

9.  A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus.

Authors:  M Federico; F Nappi; G Ferrari; C Chelucci; F Mavilio; P Verani
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex.

Authors:  Jason O'Donnell; Kenneth A Taylor; Michael S Chapman
Journal:  Virology       Date:  2009-01-13       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.